DNA chain - ELE Biotech

A new standard in early detection of dementia


ELEarly Dementia. A blood test for early dementia risk screening.

Blood test · Early detection · In clinical development
Hero mobile - ELE Biotech
DNA chain - ELE Biotech

A new standard in early detection of dementia


ELEarly Dementia. A blood test for early dementia risk screening.

Blood test · Early detection · In clinical development

MISSION


MISSION

ELE Biotech has arrived with the purpose of addressing an urgent need in society: dementias, which affect more and more people every day. Our mission is clear: to detect dementia before symptoms appear. At ELE Biotech we research, develop and put science at the service of society to improve the quality of life of millions of people.


ELE Biotech has arrived with the purpose of addressing an urgent need in society: dementias, which affect more and more people every day. Our mission is clear: to detect dementia before symptoms appear. At ELE Biotech we research, develop and put science at the service of society to improve the quality of life of millions of people.


Early Detection

The cornerstone of ELE Biotech is the early detection of neurodegenerative diseases through our biomarker.

Life Quality

At ELE Biotech, we firmly believe that early dementia detection improves patients' hope and quality of life.

Enhanced Research

ELE Biotech is a start-up with a strong focus on R&D in biomarkers and diagnostics. Continuous improvement is our only option.

Early Detection

The cornerstone of ELE Biotech is the early detection of neurodegenerative diseases through our biomarker.

E
L

Life Quality

At ELE Biotech, we firmly believe that early dementia detection improves patients' hope and quality of life.

Enhanced Research

ELE Biotech is a start-up with a strong focus on R&D in biomarkers and diagnostics. Continuous improvement is our only option.

E


The data speaks

Quantitative Evidence

The problem of dementia is urgent and global. The numbers speak for themselves.

55 million people with dementia
55M

×3 in 2050

People suffer from dementia worldwide today, and this figure is projected to triple by 2050

75% of cases undiagnosed
75%

Of cases remain undiagnosed, delaying referral, treatment and necessary social support

2 to 5 years diagnostic delay
2–5years

From the first symptoms to diagnosis, a key window for early detection

OUR TEAM

OUR TEAM


The founders have been friends since childhood. They built their careers separately - one becoming a scientist at centres of excellence, the other building and managing companies - but have joined forces to address an unmet need: early dementia screening. The multidisciplinary team has the perfect combination of experience to bring our device to market through ELE Biotech.


The founders have been friends since childhood. They built their careers separately - one becoming a scientist at centres of excellence, the other building and managing companies - but have joined forces to address an unmet need: early dementia screening. The multidisciplinary team has the perfect combination of experience to bring our device to market through ELE Biotech.


Laura Vallés Saiz

CEO & Co-Founder

Elena Calvo Cantero

COO & Co-Founder

Rocío de Dios Segovia

Officer Manager

Francisco Vallejo Bedia

Product Development

Patricia Martínez Pérez

Regulatory & Clinical Project

Associate

Jesús Ávila de Grado

Expert Advisor

Laura Vallés Saiz

CEO & Co-Founder

Sergio Sánchez García

IT Manager

Elena Calvo Cantero

COO & Co-Founder

Francisco Vallejo Bedia

Product Development

Rocío de Dios Segovia

Officer Manager


Jesús Ávila de Grado

Expert Advisor

Patricia Martínez Pérez

Regulatory & Clinical Project Associate



Ready to learn more?

Want to learn about ELEarly Dementia?

We put science at the service of society. Contact us and discover how ELE Biotech is changing dementia diagnosis.

Contact us